Article

Alopecia areata and relationship with stressful events in children.

’Cetatea Histria’ Polyclinic, Bucharest, Romania.
Journal of the European Academy of Dermatology and Venereology (Impact Factor: 2.69). 05/2008; 23(1):107-9. DOI: 10.1111/j.1468-3083.2008.02748.x
Source: PubMed
0 Bookmarks
 · 
48 Views
  • Source
    Vitiligo - Management and Therapy, 12/2011; , ISBN: 978-953-307-731-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective: We sought to determine whether anti-depressive therapy could enhance the efficacy of dermatological treatment in alopecia areata patients who suffer from major depressive disorder. Methods: Sixty patients were enrolled in the study. Thirty patients with alopecia who were diagnosed with major depressive disorder received 20 mg/day citalopram and 5 mg/ml triamcinolone injection every 4 weeks, up to six injections, and 30 patients received only triamcinolone injection each month for 6 months using a simple random method. Results: The mean diameter of the alopecic patches in the triamcinolone injection only group versus the combined treatment group [psychiatric (citalopram) plus dermatologic treatment] before treatment was 2.7 ± 0.7 (mean ± SD) and 2.5 ± 1.8, respectively, with no statistically significant differences (Mann- Whitney, P=0.08). After 6 months of therapy, the mean diameter of patches reached 1.6 ± 1 and 0.54 ± 0.97 in the triamcinolone injection only group and the combined treatment groups, respectively (Mann- Whitney, P<0.0001). Discussion: The results of this study showed that anti-depressive treatment might help to improve alopecia areata in patients with major depressive disorder.
    Journal of Dermatological Treatment 01/2013; · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The literature review for 2009 covers the principal themes of the speciality and brings new findings in the fields of pathophysiology, clinical features, therapeutical approaches. With regards to atopic dermatitis, we noticed new studies on potential inducing factors (breastfeeding, probiotics, food, vitamins, prematurity, Staphylococcus aureus and constipation). There are also new data on therapy using tacrolimus. With regards to vascular anomalies and especially haemangiomas, the literature comprises new data on evolution and efficacy of propranolol. With regards to congenital nevi, there are studies related to treatment and complications. With regards to warts, the literature brings news about virus transmission and therapy. With regards to genodermatosis (neurofibromatosis type I, cutis laxa, pseudoxanthoma elasticum, epidermolysis bullosa, ichtyoses and pilar diseases), we found novel facts in the fields of molecular analysis, clinical aspects, pathophysiology and quality of life. The literature in 2009 also contains studies on Lyell syndrome, Kawasaki disease, vitiligo, psoriasis, pityriasis rubra pilaris, urticaria and alopecia areata.
    Annales De Dermatologie Et De Venereologie - ANN DERMATOL VENEREOL. 01/2009; 136.